Overview
Genetic epidemiology of prostate cancer
Hanna Rennert, Ph.D., F.A.C.M.G. is Assistant Professor of Pathology and Laboratory Medicine at Weill Medical College of Cornell University, and Director of the Molecular Pathology Laboratory at the New York Presbyterian Hospital – Weill Cornell Medical Center. She received her Ph.D. in Biochemistry from the Technion-Israel Institute of Technology Medical School. Following postdoctoral training at the University of Pennsylvania, Dr. Rennert served in oversight roles within the Molecular Pathology Laboratory in the Department of Pathology and Laboratory Medicine. From 2000 until 2002, she directed a Microarray Research and Development Laboratory at Tel-Aviv Sourasky Medical Center. Dr. Rennert rejoined the University of Pennsylvania School of Medicine in 2002 as a Senior Molecular Genetics Scientist and adjunct faculty in Molecular Pathology. She is certified by the American Board of Medical Genetics in Clinical Molecular Genetics, and is obtaining a certificate in Clinical Epidemiology from the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania. Dr. Rennert directed the Molecular Diagnosis and Genotyping Facility within the Pathology Department until July 2005 when she came to Weill Cornell Medical College.
Highlights
- 1The Journal of molecular diagnostics : JMD · 2023
- 2Diagnostic microbiology and infectious disease · 2022
- 3The Journal of molecular diagnostics : JMD · 2020
Publications
Funding
Active
1 grant- Co-IR01DK139336-01A1QSM for detection of hemorrhaging cysts and risk stratification in ADPKDNational Institute of Diabetes and Digestive and Kidney Diseases · 2025–2029
Completed grants (4)
- PIVPI 204791-01Master Services Agreement with VertexVertex Pharmaceuticals · 2020–2025Contract
- Co-IR37AI051652-15S1Biomolecular Markers for Safe Minimization of ImmunosuppressionNational Institute of Allergy and Infectious Diseases · 2014–2022· 2 renewals
- PISRA 192028-01Sponsored Research Agreement Vertex and Dr. Hanna Rennert (WCM)Vertex Pharmaceuticals · 2019–2020Contract
- PISRA 190021-01SRA Amendment No. 1 (changing payment term deadlines)Vela Diagnostics · 2018–2019Contract
News mentions
- Researchers Create Rapid Diagnostic Tests and Multi-Omics Analytics Platforms for SARS-CoV-2 InfectionMarch 30, 2021
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.